Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
April 20, 2020

Incyte begins Phase III trial of ruxolitinib to treat Covid-19

Incyte has started a Phase III clinical trial of ruxolitinib (Jakafi) to treat cytokine storm caused by Covid-19 coronavirus infection.

The global, randomised, double-blind, placebo-controlled Phase III trial, named RUXCOVID, will assess the safety and efficacy of ruxolitinib given along with standard-of-care (SoC) in around 400 patients aged ≥12 years worldwide.

RUXCOVID is funded by Incyte in the US and Novartis outside of the US. Earlier this month, Incyte and Novartis announced plans to conduct the Phase III trial.

Read the full article here

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU